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OBJECTIVES: With constant incentives for health care payers to contain their 
pharmaceutical budgets forecasting has become critically important. Some 
countries even developed pharmaceutical horizon scanning units. The objective of 
this project was to build a model to assess net effect of the entrance of new 
patented medicinal products versus medicinal products going off-patent, with a 
forecast horizon until 2016, on seven selected EU Member States’ pharmaceutical 
budgets: France, the UK, Germany, Poland, Portugal, Greece and Hungary. This 
model should take into account the ageing population, as well as current and future 
country-specific pricing, reimbursement and market access policies. (performed for 
the EU Commission -http://ec.europa.eu/health/healthcare 
/key_documents/index_en.htm) METHODS: A model was developed for generics 
and biosimilars for each country. This model estimated a separate and combined 
effect of the direct and indirect impact of patent cliff. A model was also developed 
for new entrants, which estimated the sales development and risk of development 
failure. New entrants were reviewed individually to assess their clinical potential 
and translate into commercial potential. Forecast was performed according to three 
perspectives (health care public payer, society and manufacturer), several types of 
distribution chain (retail, hospital, combined retail and hospital). Probabilistic and 
deterministic sensitivity analyses were carried out. RESULTS: All countries would 
experience drug budget reduction except Poland (€+41 million). Savings are 
expected to be the highest in the UK (€-9367 million), France (€-5589 million), and 
far behind, followed by Germany (€-831 million), Greece (€-808 million), Portugal (€-
243 million) and Hungary (€-84 million). Cardiovascular, central nervous system , 
respiratory areas and biosimilar entry will be the source of savings, while oncology, 
immunology and inflammation will lead for additional expenditure. The model is 
very sensitive to time to market branded products, generic prices, geneneric 
penetration, distribution of biosimilars. CONCLUSIONS: Pharmaceutical 
expenditures are expected to decrease in the analyzed period. The model is 
sensitive to policy decisions.  
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OBJECTIVES: Current mechanisms of pharmaceutical price control, as for instance 
international price referencing, may result in a convergence of pharmaceutical 
prices across countries at different levels of economic attainment. Within the EU, 
this process is intensified through the single European Market, which fosters 
parallel trade if price discrepancies for pharmaceuticals are sufficiently large. A 
narrow pharmaceutical price corridor within the EU should lead to 
disproportionally high percentages of pharmaceutical spending on total health 
care spending in lower income EU countries. This paper explores whether such a 
discrepancy exists between European countries after controlling for other factors 
potentially influencing the level of pharmaceutical spending. METHODS: We 
analysed OECD and EUROSTAT data from 21 European countries between 2001 
and 2010. A two-level hierarchical growth curve model was used to assess the 
relationship between pharmaceutical expenditure as percentage of total health 
expenditure and covariates both on measurement and country-level, including 
GDP, pharmaceutical and total health expenditure per capita, the cost of labour in 
EU member countries and life expectancy at birth. RESULTS: Initial results show 
an inverse relationship between GDP per capita and pharmaceutical expenditure 
as a percentage of total health expenditure. This relationship remains highly 
significant even after controlling for life expectancy at birth and differences in 
labour cost across EU member states. CONCLUSIONS: Pharmaceutical pricing 
policies within the EU put disproportionally high pressure on countries with more 
restricted health care budgets, which further limits access to health care - and 
thereby the potential to achieve health benefits - in lower income EU countries. 
Future analysis should use more disaggregated data and link pharmaceutical 
prices to health status and data on actual pharmaceutical consumption. 
Ultimately, new strategies of establishing differential pharmaceutical pricing 
across countries at different levels of economic attainment are needed to ensure 
universal and equitable access to innovative health care technologies.  
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OBJECTIVES: This study examines the dynamics of out-of-pocket health care 
spending by looking at the persistence of such spending among Medicare 
beneficiaries. It provides insight into how long high health care out-of-pocket 
spending persists, its association with certain health conditions and health 
shocks, and identify the determinants of the likelihood that an individual will be 
a persistent high health care spender. METHODS: This study uses the Health and 
Retirement Study (HRS) from 2001 to 2010. Descriptive statistics show 
concentration and persistence of out-of-pocket health care spending. Logistic 
model is used to study the likelihood of persistently being in the top percentiles 
of out-of-pocket health care spending among elderly adults who were initially in 
the top percentiles and to identify determinants of such probabilities. RESULTS: 
High out-of-pocket spending persisted for about six years and then remained 
fairly stable afterwards. Having a certain health condition such as diabetes, 
strokes or emotional problems increased the probability of persistence by up to 9 
percentage points. Compared to elderly adults who were covered by only 
Medicare, people having other government health insurance such as Medicaid, 
CHAMPUS, VA, or other military programs were about 19 percentage points less 
likely to be a persistently high out-of-pocket spender. By contrast, people who 
were covered by Medicare and any supplementary health insurance were more 
likely to be a persistently high spender. CONCLUSIONS: Non-trivial number of 
elderly adults remained in the same upper percentiles of the distribution for 
multiple years. The crucial factors that triggered high out-of-pocket spending on 
health care for several years were having certain chronic conditions or 
experiencing the onset of new health condition, even after controlling individual 
characteristics. Additionally, having an existing health insurance that 
supplements Medicare coverage or the acquisition of a new supplementary 
health insurance had a significant impact on the probability of persistence.  
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OBJECTIVES: Budget impact analysis (BIA) should be used alongside cost-
effectiveness analysis (CEA) to inform formulary decision-making. In the present 
analysis, US-published BIAs of pharmacological interventions were analyzed to 
assess trends in reported outcomes and conclusions. METHODS: Systematic 
searches (01/2002-12/2012) of PubMed and other sources (i.e., ISPOR/AMCP 
proceedings, manual reference search) were conducted to identify published 
BIAs reporting per-member per-month costs (PMPMC or equivalent) associated 
with the introduction of new pharmacotherapies. The outcome measures 
(PMPMC and BIA-author judgments of their own results) were analyzed 
descriptively. Associations between these two measures and other study 
characteristics (publication year and type, analytical horizon, and patient 
population size) were evaluated. RESULTS: Fifty BIAs were identified (40% via 
PubMed), reporting a total of 82 PMPMC outcome estimates (as some studies 
reported multiple populations/indications). Half were published in/after 2009. 
The median (min; max) PMPMC across all 82 estimates was 2 (-66; 894) cents 
(US$). Thirteen percent of all estimates were cost-saving while 75% and 95% 
were ≤5 and ≤90 cents, respectively. 65% of studies reported results between -5 
and +5 cents PMPM. No study characteristics were associated with PMPMC. In 
84% of studies the authors provided qualitative judgments of the acceptability of 
their BIA results. In 6% of studies and estimates, the PMPMC was reported as 
unacceptable. CONCLUSIONS: BIA results cluster within a narrow range (-5 to +5 
cents) and are nearly always reported as acceptable. These findings raise 
questions regarding the relevance and validity of published BIAs. In part, BIAs 
expressed in PMPMC (particularly in cents on the dollar) may easily provide a 
false impression of minimal impact. Whether BIA authors should self-judge the 
acceptability of PMPMC estimates is questionable. Without pre-defined 
benchmarks, judgments regarding BIA acceptability may be best left to decision-
makers and within the context of more comprehensive assessment (including 
notably CEA results).  
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OBJECTIVES: With constant incentives for health care payers to contain their 
pharmaceutical budgets, modelling policy decision impact become critical. The 
objective of this project was to test various policy decisions on pharmaceutical 
budget (developed for the European Commission for the project “EU 
Pharmaceutical expenditure forecast” -http://ec.europa.eu/health/healthcare/ 
key_documents/index_en.htm). METHODS: We built a model to assess policy 
scenarios impact on pharmaceuticals reference forecast for seven EU Member 
States (France, the UK, Germany, Poland, Portugal, Greece and Hungary). The 
following scenarios were tested: expanding UK policies to EU, time to market 
access, reimbursement rate , generic price and penetration, distribution chain of 
biosimilars. RESULTS: Applying the UK policy would incur dramatic savings for 
Germany (10 times the reference forecast). France and Portugal would also enjoy 
substantial additional savings under this scenario (2 and 4 times the reference 
forecast respectively). Delaying time to market is very powerful to reduce the 
pharmaceuticals expenditure. While applying the EU transparency directive (6 
month-process for pricing and reimbursement), it would increase budget for all 
countries (from 1.1 to 4 times the reference forecast), except in Germany 
(additional savings). Decreasing price of generic and boosting the penetration 
rate, associated to distribution of biosimilar through hospital channel is a 
powerful way to reduce pharmaceuticals expenditure.In comparison, 
reimbursement rate has a modest impact. CONCLUSIONS: The most important 
leverages that were identified by the model on the pharmaceutical budget are 
driven by generic and biosimilar prices penetration rate and distribution. 
Reducing, even slightly, the prices of generics will have a major impact while 
reimbursement rate has less impact. Time to access for innovative products is an 
effective leverage used by some countries for delaying the bill.  
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BACKGROUND: The Mexican institute for social security IMSS represents alone 
44% of the total health care market in the country. Selling to this major client 
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requires each drug to be listed in the national drug formulary according to a law 
passed in 2002. The objective of this law was to certify not only the safety profile 
of every new drug, but also its economical benefits based on a 
pharmacoeconomical study that must be presented for evaluation. OBJECTIVES: 
To analyze if the expenditure made by the IMSS in 2011 used the cost-
effectiveness criteria based on the drugs listed in the national formulary. 
METHODS: Six high resource consuming diseases in the country were selected 
together with their respective prescribed treatments. Each prescribed treatment 
was classified according to three parameters: - Less expensive treatment - Most 
expensive treatment - Cost-effective treatment Prices of each treatment and its 
total expenditure were obtained through the institute’s official purchase portal. 
Pharmacoeconomical studies needed to obtain the cost effective treatment were 
already evaluated for drug's inclusion in the national formulary. Results were 
analyzed to evaluate the expenditure's nature. RESULTS: In a half of the studied 
diseases, the expenditure on other none cost-effective treatments represented at 
least 50% more than for the cost-effective ones. The total expenditure on the 
studied cases was US $226,881,190.64. From these consumed resources, 33.54% 
was used to buy other non cost-effective drugs. From the observed purchases 
made, 40% were direct adjudications not open to competition. CONCLUSIONS: 
Even though every new drug is being evaluated since year 2002 to show its 
economical benefits, the studied institution in not fully using the cost-
effectiveness criteria to buy its drugs in Mexico, even in some of the most 
resource consuming diseases.  
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OBJECTIVES: This paper examines which families bear the heaviest financial 
burden from recent changes in cost-sharing provisions of employment-based 
health insurance among different socioeconomic and health statuses 
characteristics. METHODS: The data source for this study is the Medical 
Expenditure Panel Survey (MEPS), a nationally representative household panel 
survey conducted by AHRQ in 2001 and 2005. We apply semi-log regression 
model to identify factors that help to explain the variation in family out-of-
pocket spending (FOOPSPD) and quantile regression to describe how FOOPSPD 
has changed throughout the out-of-pocket spending distribution and thus to 
assess the effectiveness of risk protection from holding employment-based 
health insurance. Additionally, a quantile regression is used to decompose the 
difference in FOOPSPD distribution into changes in family characteristics and 
changes in structural factors. RESULTS: Between 2001 and 2005, average 
FOOPSPD had significantly increased by 22%. Econometric findings showed that 
having one more health conditions increased FOOPSPD by up to 11%. 
Additionally, the biggest increase in FOOPSPD occurred among families who 
were in the top quantiles of the FOOPSPD distribution with certain health 
conditions. Among 11 major high-cost health conditions, having COPD or asthma 
and/or hypertension were the two key conditions that triggered the biggest 
increases in FOOPSPD burdens. The results from the decomposition analysis 
revealed that more than 80% of changes in FOOPSPD were associated with the 
structural changes. CONCLUSIONS: Families who relied more on health care 
because of one or more family members’ existing health conditions were most 
affected by changes in cost sharing during the study period. In addition, 
decreases in the “return” to risk protection from holding private health 
insurance, in terms of increased exposure to premium payments and out-of-
pocket medical spending, occurred primarily for families who spent the least and 
the most out-of-pocket for medical care experienced greater increase in 
FOOPSPD.  
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OBJECTIVES: Today, we observe quite a disruption over most countries in value 
appreciation of new drugs, that is making historical data used for forecasting 
pharmaceutical expenditure poorly reliable. Forecasting methods rarely 
addressed uncertainty. The objective of this project was to propose a 
methodology to perform pharmaceutical expenditure forecast integrating 
expected policy changes and uncertainty (developed for the European 
Commission: “EU Pharmaceutical expenditure forecast” http://ec.europa.eu/ 
health/healthcare/key_documents/index_en.htm METHODS: 1) Identify all 
pharmaceuticals going off-patent and new branded medicinal products, over 5-
year forecasting period, in seven EU Member States; 2) Develop a model to 
estimate direct and indirect impact (based on health policy and clinical experts) 
on savings of generics and biosimilars. Inputs were originator sales value, patent 
expiry date, time to launch after marketing authorization, price discount, 
penetration rate, time to peak sales, impact on brand price; 3) Develop a model 
for new entrants, which estimated sales progression in competitive 
environment. Clinical expected benefits as well as commercial potential were 
assessed for each product by clinical experts. Inputs were development phase, 
marketing authorization dates, orphan condition, market size, competitors; 4) 
Analyze separately budget impact of products going off-patent and new entrants 
according to several perspectives, distribution chain and outcomes; and 5) 
Address uncertainty surrounding estimations via deterministic and probabilistic 
sensitivity analysis. RESULTS: This methodology allowed 1) to identify main 
parameters impacting pharmaceutical expenditure forecast varying across 
countries: generics discounts and penetration, brand price after patent loss, 
reimbursement rate, penetration of biosimilars and discount price, distribution 
chain, time to peak sales for new entrants; 2) to define probability of occurrence 
of a pre-determined impact thanks to probabilistic analysis; and 3) to test 
different pricing and reimbursement policy decisions on health expenditures. 
CONCLUSIONS: This methodology is independent of historical data and appears 
to be highly flexible and adapted to test robustness and provide probablisitic 
analysis to support policy decision making.  
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OBJECTIVES: Many clinical measures and patient-reported quality-of-life scores 
correlate with health care resource use, but their relative predictive value is 
understudied. This analysis compares a well-established physical-health-related 
quality of life measure against comorbidity status and current medical visits in 
their ability to predict the number of doctor visits three months later. METHODS: 
Data are drawn from a 2009 study of a general US representative sample in 
which a subset were reinterviewed after approximately 3 months (n=470). Study 
measures included a comorbidity checklist, a self-reported count of medical 
visits in the preceding four weeks, and the SF-36 or SF-12 physical component 
summary (PCS) measure. We constructed three logistic regression models 
estimating the probability of higher resource use (self-report of 2+ medical visits 
in the past four weeks vs. 1 or none) after three months. Model 1 included the 
number of comorbidities (none; 1; 2-3; 4+) and resource use (count of medical 
visits) at baseline as independent variables. Model 2 included just PCS at 
baseline, and model 3 included all predictors from models 1 and 2. RESULTS: 
Models 1 (AUC=0.77, pseudo-R2=0.16) and 2 (AUC=0.76, pseudo-R2=0.14) have 
roughly the same explanatory power, suggesting that PCS has predictive ability 
similar to counts of comorbidities and medical visits. For example, a 5-point 
lower PCS at baseline is associated with a 50% increase in the odds of having 2+ 
medical visits three months later (Model 2), an association similar to that of one 
more medical visit at baseline or being in a higher comorbidity count category 
(Model 1). Model 3 (AUC=0.80, pseudo-R2=0.19) improves somewhat on both 
models. CONCLUSIONS: Our results suggest that as compared to comorbidity 
counts and number of medical visits, PCS alone has similar ability to predict 
having 2+ doctor visits during a four week period three months later.  
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OBJECTIVES: There is no study empirically comparing the racial disparity in 
hospital inpatient cost between homeless and non-homeless patients. This paper 
compares hospital inpatient costs between homeless and non-homeless patients 
across race groups. This paper further provides comprehensive descriptive 
information on patient characteristics, insurance coverage, disease prevalence, and 
severity of illness for homeless patients and non-homeless patients by race groups. 
METHODS: We employed propensity score matching to create two cohorts, where 
inpatient hospital visits between homeless and non-homeless patients were 
matched based on patients’ demographics and clinical information, and hospital 
types. These new similar cohorts were then used to compare the cost per hospital 
visit between homeless and non-homeless patients through multivariate regression 
analysis. The Healthcare Cost and Utilization Project (HCUP) State Inpatient 
Databases (SID) for 2009 were used. Data were drawn from 579 hospitals reporting 
data on homelessness in Arizona, California, Colorado, Florida, Georgia, 
Massachusetts, Missouri, New York, Pennsylvania, and Wisconsin. SID provide 
detailed diagnoses, procedures, total charges and patient demographics including 
homelessness. We linked SID files with American Hospital Association Annual 
Survey Database and Area Resource File to obtain hospital and area level 
characteristics. RESULTS: We find significant variations in hospital inpatient costs 
between homeless and non-homeless patients across race groups. Our risk adjusted 
results show that homeless patients generally have lower inpatient costs when 
compared to non-homeless patients. We find that homeless white patients have 
higher inpatient costs and non-homeless white patients have lower inpatient costs 
when compared to their homeless non-white and non-homeless non-white 
counterparts respectively. We also find that the majority of homeless children at 
hospital inpatient departments are non-white. In addition, about a third of all 
inpatient hospital visits by white homeless patients are for female individuals. 
CONCLUSIONS: This study provides comprehensive empirical evidence for racial 
disparity in hospital inpatient costs between homeless and non-homeless patients.  
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OBJECTIVES: To develop and test a measure of outpatient prescription 
medication utilization (medication exposure measure – MEM) that may be 
coupled with the CMS-HCC and CMS-RxHCC methodologies to improve CMS risk-
adjusted capitated payments to Medicare Part C and Part D plans. The MEM 
should be more difficult for health plans and providers to manipulate compared 
with unique drug or prescription counts. MEM is operationalized as the average 
number of unique drugs that an individual possesses over a specified time 
